Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2025-02-14 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Integrated Filing- Financial
Regulatory Filings
2025-02-14 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges and regulatory bodies, referencing Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a U.S. FDA inspection at the company's manufacturing facility and the issuance of a Form 483 with observations. The document is short (2341 characters) and serves as an announcement of an event related to regulatory compliance and inspection results. It does not contain financial data, audit results, or detailed management discussion. It is not a full report but a regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-14 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting held on February 14, 2025. It details the appointment and re-appointment of directors, including their profiles and terms, as well as the reconstitution of Board Committees. The content focuses on changes in the company's board of directors and committee compositions. There is no financial data, earnings information, or report publication mentioned. The document is not a full annual or interim report, nor is it a proxy solicitation or voting result announcement. It clearly fits the category of Board/Management Information (MANG) as it announces changes in the company's board of directors and senior management positions.
2025-02-14 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation – Q3 FY 24-25' and is addressed to stock exchanges pursuant to SEBI regulations, indicating it is an official investor communication. It contains detailed financial data for the third quarter of fiscal year 2025, including consolidated revenue, regional highlights, profitability metrics like EBITDA and PAT, and segment-wise performance. The document includes forward-looking statements, disclaimers about unaudited data, and strategic outlook commentary from the Chairman and Managing Director. The length is substantial (15,000 characters), and the content is consistent with a detailed presentation aimed at investors, focusing on financials, strategy, and market position. There is no indication that this is a full annual or quarterly report filing, nor is it a brief earnings release or a regulatory announcement. Therefore, the document fits the definition of an Investor Presentation (IP).
2025-02-14 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated February 14, 2025, from Glenmark Pharmaceuticals Limited, announcing financial results for the third quarter ended December 31, 2024. It includes detailed financial figures such as consolidated revenue, EBITDA, and PAT margins, along with segment-wise performance and business highlights. The document also contains a Management Discussion & Analysis (MD&A) section discussing operational review, market share, and product updates. The presence of comprehensive financial data and management commentary for a quarterly period indicates this is a substantive interim financial report. It is not merely an announcement or a brief summary but contains detailed financial results and analysis for the quarter. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2025-02-14 English
Financial Result Updates
Regulatory Filings
2025-02-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.